XOMA Co. (NASDAQ:XOMAO – Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 4,882 shares, a decline of 24.7% from the January 29th total of 6,480 shares. Based on an average daily trading volume, of 2,853 shares, the short-interest ratio is currently 1.7 days. Based on an average daily trading volume, of 2,853 shares, the short-interest ratio is currently 1.7 days.
XOMA Stock Performance
Shares of XOMAO opened at $25.44 on Monday. The business has a 50-day moving average of $25.39 and a 200-day moving average of $25.42. XOMA has a 1 year low of $23.32 and a 1 year high of $25.76.
XOMA Company Profile
XOMA Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies. The company applies its proprietary protein engineering and antibody optimization platform to generate novel drug candidates targeting autoimmune, inflammatory and metabolic diseases. XOMA’s scientific expertise spans antibody discovery, engineering, in vitro and in vivo testing, and early‐stage clinical development.
In addition to advancing its own pipeline of antibody candidates, XOMA collaborates with pharmaceutical and biotechnology partners to provide research and development services.
Further Reading
- Five stocks we like better than XOMA
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
